Stonepine Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Stonepine Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200,000	Closed	-$1.86M	–	86
2025 Q4	$1.86M	Sell	200,000 -447,382	-69%	-$3.74M	1.36%	23
2025 Q3	$4.56M	Buy	647,382 +197,382	+44%	+$1.36M	3.71%	6
2025 Q2	$2.92M	Buy	450,000 +101,180	+29%	+$696K	2.87%	11
2025 Q1	$2.77M	Buy	348,820 +113,820	+48%	+$1.23M	2.69%	14
2024 Q4	$2.98M	Buy	235,000 +29,325	+14%	+$408K	2.4%	15
2024 Q3	$2.87M	Buy	+205,675	New	+$2.93M	1.81%	18

Other funds holding DAWN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Stonepine Capital Management's DAWN Position: Q1 2026 in Review

Stonepine Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 200,000 shares — an estimated $1.86M sold.

Stonepine Capital Management first reported a position in DAWN in Q3 2024 and held it in 6 quarters. The position peaked at $4.56M in Q3 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

Stonepine Capital Management reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
Stonepine Capital Management sold 200,000 Day One Biopharmaceuticals shares in Q1 2026, an estimated $1.86M.
Stonepine Capital Management first reported a position in Day One Biopharmaceuticals in Q3 2024 and held it in 6 quarters.
Stonepine Capital Management's Day One Biopharmaceuticals position peaked at $4.56M in Q3 2025.
206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.